NCT04616209View on ClinicalTrials.gov

Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 15, 2020

Primary Completion Date

December 30, 2027

Study Completion Date

December 31, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

donor-derived NK cell infusion

PB103 administrations will be separated by 4-week interval

Trial Locations (1)

11490

RECRUITING

Tri-Service General Hospital, Taipei

All Listed Sponsors
collaborator

Tri-Service General Hospital

OTHER

lead

Precision Biotech Taiwan Corp.

INDUSTRY